Previous 10 | Next 10 |
WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,...
2023-05-21 10:03:52 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re a risk taker on the lookout for stocks with 1000% upside potential, you’d have to venture into speculative territory. It is difficult to find analyst ratings with such...
2023-05-15 16:58:49 ET Checkpoint Therapeutics press release ( NASDAQ: CKPT ): Q1 GAAP EPS of -$0.89. For further details see: Checkpoint Therapeutics GAAP EPS of -$0.89
WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2023, and recent corporate highlights. ...
Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half of 2023 PDUFA goal date of January 3, 2024 set by FDA for cosibelimab to treat metastatic or locally advanced cutaneous squamous cell carcinoma MIAMI, May 15, 2023 (G...
2023-04-05 10:07:20 ET Gainers: Liminal BioSciences ( LMNL ) +81% . InflaRx ( IFRX ) +51% . 180 Life Sciences ( ATNF ) +26% . YS Biopharma ( YS ) +22% . Immunic ( IMUX ) +21% . Losers: Bullfrog AI ( BFRG ) -15% ....
2023-04-05 02:40:09 ET Summary The Company has a January 3rd, 2024 PDUFA date on its lead compound, cosibelimab, an anti-PD-L1 antibody that was developed for locally advanced and metastatic cutaneous squamous cell carcinoma (cSCC). Cosibelimab has better efficacy than Merckȁ...
2023-03-31 10:05:49 ET Gainers: Y-mAbs Therapeutics ( YMAB ) +43% . G Medical Innovations ( GMVD ) +41% . Palisade Bio ( PALI ) +20% . Inozyme Pharma ( INZY ) +17% . Paratek Pharmaceuticals ( PRTK ) +17% . Losers: Pyxis...
2023-03-31 08:32:30 ET Checkpoint Therapeutics ( NASDAQ: CKPT ) entered into definitive agreements for the issuance and sale of 1.7M shares of its common stock at a purchase price of $3.60/share in a registered direct offering. Also, in a concurrent private place...
WALTHAM, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1...
News, Short Squeeze, Breakout and More Instantly...
Checkpoint Therapeutics Inc. Company Name:
CKPT Stock Symbol:
NASDAQ Market:
Checkpoint Therapeutics Inc. Website:
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Check...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoin...
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional in...